Drug Trial Radar · NCT07935369
RC118 Combined With RC148 as First-Line Treatment for Claudin 18.2-Positive, HER2-Negative Advanced G/GEJ Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
680
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Apr 30, 2030
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- RemeGen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, controlled, open-label, multicenter Phase II/III study evaluating the efficacy and safety of RC118 (an antibody-drug conjugate targeting Claudin 18.2) in combination with RC148 versus PD-1 inhibitor (Tislelizumab) plus chemotherapy (CAPOX) as first-line treatment in patients with Claudin 18.2-positive and HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The study consists of two phases: Phase II will explore the optimal dose combination of RC118 and RC148 across three experimental arms versus a standard comparator arm. Phase III will evaluate the efficacy (progression-free survival) of the recommended Phase III dose (RP3D) combination versus standard of care.
Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Interventions
RC118(Dose 1) plus RC148(Dose 1)Drug
Dose1+Dose1
RC118(Dose 1) plus RC148(Dose 2)Drug
Dose1+Dose2
RC118(Dose 2) plus RC148(Dose 1)Drug
Dose2+Dose1
Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine TabletsDrug
Tislelizumab (200 mg Q3W) + Oxaliplatin (130 mg/m² Q3W, max 6 cycles) + Capecitabine (1000 mg/m² BID, D1-14 Q3W)
RC118 plus RC148 (phase III)Drug
The dose for Phase III will be determined based on Phase II results.
Tislelizumab Injection plus Oxaliplatin for Injection plus Capecitabine Tablets (phase III)(phase III)Drug
Tislelizumab (200 mg Q3W) + Oxaliplatin (130 mg/m² Q3W, max 6 cycles) + Capecitabine (1000 mg/m² BID, D1-14 Q3W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- (phase II)Objective Response Rate assessed by the investigators according to RECIST v1.1Time frame: From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months.
- (phase III)Progression-Free Survival assessed by the BIRC according to RECIST v1.1Time frame: From randomization date until disease progression, lost to follow-up, withdrawal of informed consent or death, assessed up to approximately 24 months.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.